Financial News
DateTitlemore >
Nov. 21, 2008Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
Nov. 19, 2008Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
Nov. 10, 2008Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
Nov. 7, 2008Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Nov. 3, 2008Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
Nov. 3, 2008Call for Applications: The Amgen Award for Science Teaching Excellence
Related Links Stock Quote


AMGN: NASDAQ
$52.79

 (Minimum 20 minute delay)